Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502030 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT04502030 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 247 participants.
The verdict
NCT04502030, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
Interventions
- OTHER Placebo
- BIOLOGICAL Panzyga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502030
The ClinicalTrials.gov registry entry for NCT04502030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04502030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502030 about?
NCT04502030 is a clinical study titled "Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)". Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
What is the current status of trial NCT04502030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2020-10-05. Estimated completion is 2025-09-19.
What interventions are being tested in trial NCT04502030?
The interventions under investigation include: Placebo (OTHER), Panzyga (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502030?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.